Schließlich hat der alle clinischen Studien zu verantworten und sicher ne Menge Info´s im Säckle.....
|
|
Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
Last updated: May 2, 2017
Estimated Enrollment: | 8 |
Study Start Date: | May 2012 |
Estimated Study Completion Date: | December 2017 |
Estimated Primary Completion Date: | December 2017 (Final data collection date for primary outcome measure) |
https://clinicaltrials.gov/ct2/show/NCT01614990
The Endocrine Society's 95th Annual Meeting and Expo, June 15–18, 2013 - San Francisco
Results: The trial is ongoing and4 out of 18 subjects havecompleted the study to date. All are men, age 68±9 years old, BMI 22.8±3.4 kg/m2, with different cancers in advanced stages. All subjects have tolerated the study medication and procedures without any difficulty. No adverse effects have been reported and the safety labs and EKG measures have been uneventful. We are still blinded to the treatment allocation as per protocol. Unblinding will occur once the first 10 subjects have finished the study, anticipated to occur approximately in May 2013 and these results will be discussed at the meeting.
http://press.endocrine.org/doi/abs/10.1210/...tings.2013.CN.8.MON-327
" Zuletzt war Ward als Chief Compliance & Legal Officer und Corporate Secretary für Sagent Pharmaceuticals tätig und führte seinen Verkauf an Nichi-Iko Pharmaceutical für 736 Millionen US-Dollar."
War das schon bekannt ? wenn ja, sorry...
Wäre ja auch eine nette Spekulation.
über 20% einer Person wird er aktiviert.
Bei einem Verkauf, Fusion ist er wohl zu vernachlässigen.
“ Acquiring Person ” shall mean any Person who is at any time after the Effective Date the Beneficial Owner of 20% or more of the outstanding Voting Shares of the Corporation; provided, however, that the term “ Acquiring Person ” shall not include:
(i) the Corporation or any corporation controlled by the Corporation;
(ii) any Person who becomes the Beneficial Owner of 20% or more of the outstanding Voting Shares as a result of one or any combination of:...............
................................
http://secfilings.nasdaq.com/...20INC.&FormType=6-K&View=html
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
25 | 17.117 | Aeterna nach dem Split | Heron | Hbit | 25.11.23 10:08 | |
9 | 13.769 | AEZS vs. KERX | Gropius | paioneer | 03.09.22 18:22 | |
19 | Wie geht's jetzt weiter mit Aeterna Zentaris? | Ebi52 | Bullish_Hope | 03.08.22 00:11 | ||
21 | 7.680 | Aeterna Zentaris Inc. | Heron | Heron | 30.09.21 23:37 | |
2 | 62 | AEterna Zentaris (AEZS)- Reboundkandidat?? | Vollzeittrader | marroni | 25.04.21 13:13 |